TRANSTHERA-B(02617) announced clinical data on the use of Tenofovir for the treatment of advanced bile duct cancer patients at the 2026 American Clinical Oncology Society's Gastrointestinal Tumor Symposium.

TRANSTHERA-B (02617) has announced that the company presented clinical data on their core product, Tenogetinib, as a monotherapy for advanced Cholangiocarcinoma (CCA) patients at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in the form of a poster. The title of the presentation was "Phase II Study of Tenogetinib in Advanced Cholangiocarcinoma: Molecular Responses and Mechanisms of Resistance". FGFR inhibitors have an established role in the treatment of Cholangiocarcinoma with FGFR2 mutations. Tenogetinib, as a novel FGFR inhibitor, has shown potential activity in overcoming acquired resistance to previous FGFR inhibitors. The presentation included analysis of circulating tumor DNA (ctDNA) biomarkers to evaluate the ability of Tenogetinib to treat CCA patients with primary FGFR inhibitor resistance, acquired FGFR inhibitor resistance due to FGFR2 fusion, and other FGFR mutations or wild-type FGFR. The presentation evaluated genomic variations in patient ctDNA and correlated efficacy based on ctDNA mutation status and patient subgroups. These results support further investigation through expanded biomarker sampling in the ongoing Phase III clinical trial.